Ling Peng

Bioimaging is a powerful tool for diagnosing tumors but remains limited in terms of sensitivity and specificity. Nanotechnology‐based imaging probes able to accommodate abundant imaging units with different imaging modalities are particularly promising for overcoming these limitations. In addition, the nanosized imaging agents can specifically increase the contrast of tumors by exploiting the enhanced permeability and retention effect. A proof‐of‐concept study is performed on pancreatic cancer to demonstrate the use of modular amphiphilic dendrimer‐based nanoprobes for magnetic resonance (MR) imaging (MRI) or MR/near‐infrared fluorescence (NIRF) multimodality imaging. Specifically, the self‐assembly of an amphiphilic dendrimer bearing multiple Gd 3+ units at its terminals, generates a nanomicellar agent exhibiting favorable relaxivity for MRI with a good safety profile. MRI reveals an up to two‐fold higher contrast enhancement in tumors than in normal muscle. Encapsulating the NIRF dye within the core of the nanoprobe yields an MR/NIRF bimodal imaging agent for tumor detection that is efficient both for MRI, at Gd 3+ concentrations 1/10 the standard clinical dose, and for NIRF imaging, allowing over two‐fold stronger fluorescence intensities. These self‐assembling dendrimer nanosystems thus constitute effective probes for MRI and MR/NIRF multimodality imaging, offering a promising nanotechnology platform for elaborating multimodality imaging probes in biomedical applications.